( NEW YORK June 22 2007 /PRNewswire-Fi...)Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois,Health

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that abstracts related to Sulonex(TM) (sulodexide oral gelcap) have been selected for publication or presentation during the poster sessions scheduled to take place at the upcoming American Diabetes Association (ADA) 67th Annual Scientific Sessions and exposition at the McCormick Place Lakeside Center in Chicago, Illinois.

Copies of these abstracts, which highlight the mechanism of action of Sulonex(TM) as well as observed clinical activity, are currently available and can be viewed on-line through the ADA website: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Locator.DisplaySea rchAbstract&CalledByID=1006

    Abstracts selected for poster presentation include the following:


    Saturday, June 23, 2007 (12:30pm-2:30pm):


    0733 - Role of Reactive Oxygen Species in High Glucose-Induced Heparanase

    Expression and Heparan Sulfate Proteoglycan Degradation in the Human

    Endothelial Cells XIULONG XU, GEETHA RAO, WENDY HUANG, RICHARD A. PRINZ,

    EDMUND J. LEWIS, Chicago, IL


    Sunday, June 24, 2007 (6:15pm-7:30pm):


    0573 - Treatment of Diabetic Nephropathy with Sulodexide: Final Phase II

    Safety and Efficacy Results EDMUND J. LEWIS, JULIA LEWIS, SAMUEL S.

    BLUMENTHAL, THOMAS WIEGMANN, LAWRENCE HUNISCKER, ITAMAR RAZ, Chicago, IL,

    Nashville, TN, Milwaukee, WI, Kansas City, KS, Iowa City, IA, Jerusalem,

    Israel


    0769 - Mechanism and Relevance of Reduced Presence of Glomerular Heparan

    Sulfate for Proteinuria in Overt Diabetic Nephropathy TESSA WIJNHOVEN,

    MABEL VAN DEN HOVEN, TOIN H. VAN KUPPEVELT, JOHAN VAN DER VLAG, JO H.

    BERDEN, RICHARD A. PRINZ, EDMUND J. LEWIS, MELVIN SCHWARTZ, XIULONG XU,

    Nijmegen, Netherlands Antilles, Chicago, IL


    Additional abstracts of inte
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase
II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple
Myeloma and Waldenstroms Macroglobulinemia
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study